Compare KYIVW & GRMLW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KYIVW | GRMLW |
|---|---|---|
| Founded | 1994 | N/A |
| Country | Ukraine | United States |
| Employees | 5000 | 5 |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | N/A | 2022 |
| Metric | KYIVW | GRMLW |
|---|---|---|
| Price | $5.50 | $0.33 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 15.0K | ★ 23.7K |
| Earning Date | 01-01-0001 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.97 | N/A |
| EPS | ★ 19.60 | N/A |
| Revenue | ★ $835,038,465.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.28 | ★ N/A |
| Revenue Growth | ★ 62.06 | N/A |
| 52 Week Low | $2.90 | $0.10 |
| 52 Week High | $5.98 | $0.37 |
| Indicator | KYIVW | GRMLW |
|---|---|---|
| Relative Strength Index (RSI) | 63.08 | 62.99 |
| Support Level | $3.15 | $0.15 |
| Resistance Level | $5.98 | $0.37 |
| Average True Range (ATR) | 0.30 | 0.06 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 65.22 | 55.81 |
Kyivstar Group Ltd is a telecommunications and digital holding company that operates Ukraine provider of mobile communication and broadband services. The company offers a wide range of connectivity and digital services, including mobile and fixed-line voice and data, ride-hailing, e-health, digital TV, and enterprise solutions such as big data, cloud, and cybersecurity. It operates through two main segments: Telecommunications and Digital. The Telecommunications segment, which generates the majority of revenue, includes service revenue from mobile and fixed connectivity services provided to both individual and corporate customers. The Digital segment comprises revenue from proprietary digital platforms and services.
Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.